Recent Updates
Recently added Catalysts
ALGS Neutral Sentiment

Lead Optimization and Selection of a Potential Best-in-Class HBV ASO

Friday, November 7, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article provides an overview of Aligos Therapeutics, focusing on their lead optimization and selection process for a potential best-in-class antisense oligonucleotide (ASO) targeting chronic HBV infection. It includes information about the company's management, pipeline, and clinical trials. However, specific details about the ASO's efficacy or development status are not provided.
Price reaction · baseline $7.1 (2025-11-06 close) · hit after-hours · 2 other ALGS headline(s) in the window, move may be shared
day 0 close
-0.4%
day 1
-3%
day 3
-9.1%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR
ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare Aligos Therapeutics HBV antisense oligonucleotide clinical trials chronic infection
Last updated: Nov 7, 2025

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →